drugset / Trial / NCT00146003
Efalizumab for Eczema
Phase 2
Completed
10 enrolled
University of Medicine and Dentistry of New Jersey
Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to demonstrate a measurable improvement on a validated scale in a small population of adult patients with atopic dermatitis (eczema).
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | efalizumab | Monoclonal antibody | — | — |